Reports
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States
Americas
Future Market Insights, Inc.
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States
MEA
Future Market Insights
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom
Asia Pacific
Future Market Insights
IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India
[280 Pages Report] The global Multiplex Biomarker Imaging Market was valued at US$ 422.1 Million in 2021 and is expected to reach US$ 1,041.7 Million by 2029, finds Future Market Insights (FMI) in a recent market survey.
Data Points | Market Insights |
---|---|
Market Value 2022 | USD 475.2 Million |
Market Value 2029 | USD 1,041.7 Million |
CAGR 2022 to 2029 | 11.9% |
Key Players | The key players are PerkinElmer Inc., Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., Abcam plc., Merck KGaA, Illumina Inc., Leica Biosystems Nussloch GmbH (Danaher Corporation), Ventana Medical Systems, Inc. (A F. Hoffmann-La Roche AG Subsidiary), Aushon BioSystems Ltd., MicroConstants, Inc., and ToposNomos Ltd. (TNL) |
Share of Top 5 Countries | 70.7% |
The growing prevalence of tumors and cancer among populations around the world and increasing demand for more effective treatment and medicine for different types of cancer are primary factors fueling the multiplex biomarker imaging market.
In addition, the growing adoption of personalized medicine is expected to drive the growth of the multiplex biomarker imaging market. Moreover, the availability of technologically advanced instruments is likely to add to the market development.
The multiplex biomarker imaging market holds nearly 1.6% market value share of the US$ 31 Billion biomarkers market in 2021. An increase in the production base of multispectral imaging devices that could provide multiplexing is expected to fuel the revenue growth of device manufacturers.
Leading manufacturers of multiplex biomarker imaging are also focusing on collaborations with laboratories and biopharmaceutical companies in order to expand their sales presence.
Driven by this, sales of multiplex biomarker imaging are expected to rise at an 11.9% CAGR through 2029.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Particulars | Details |
---|---|
H1, 2021 | 11.88% |
H1, 2022 Projected | 11.86% |
H1, 2022 Outlook | 11.76% |
BPS Change - H1, 2022 (O) - H1, 2022 (P) | (-) 10 ↓ |
BPS Change - H1, 2022 (O) - H1, 2021 | (-) 12 ↓ |
The multiplex biomarker imaging market is subject to influence by the rising inpatient base with tumors, and technological developments by the impact of macro and industry factors. FMI presents a comparative analysis of the market growth rates and development prospects in the global multiplex biomarker imaging market.
According to Future Market Insight analysis, the multiplex biomarker imaging market will drop by 12 Basis Point Share (BPS) in H1-2022 (O) compared to H1-2021. The preservation of discrete microenvironment morphology may be compromised in multiplex biomarker imaging due to lack of resolution or because of sampling time, it is difficult to preserve the immunolabeling with morphology.
This is the major reason for the drop in BPS attributed to the decline in shares. The H1-2022 outlook period in comparison to H1-2022 projected period showed a negative growth in terms of Basis Point Share by 10 BPS.
Despite the factors, some plus points stay ahead for the industry including technological advancements such as faster scanning time and higher sensitivity and emerging players entering into supply and distributor partnerships to expand their market reach.
Sales of multiplex biomarker imaging grew at a CAGR of 13.5% between 2012 and 2021.
The multiplex biomarker imaging market is expected to show rapid growth owing to the increasing prevalence of chronic diseases, rising adoption of personalized medicine, and a broad range of benefits of multiplex imaging over traditional imaging.
In addition, the high prevalence of cardiac and cancer problems, advancements in biomarkers, and increased application are the key factors contributing to market development. The surge in cancer cases worldwide has led to an increase in the use of biomarkers with the development of technology. As per the WCRF (World Cancer Research Fund International), about 18 million cases were there across the world in 2020. Also, the global burden of cancer cure and prevention is the chief concern for pharmaceutical and government companies.
Considering this, FMI expects the global multiplex biomarker imaging market to grow at a CAGR of 11.9% through 2029.
The complexity of the process and unclear regulatory guidance on the commercial sale of digital pathology imaging products are anticipated to hamper the multiplex biomarker imaging market growth. There is unclear regulatory control on the commercial diagnostic use of whole slide imaging (WSI) products comprising multiplex biomarker imaging systems.
In addition, a lack of awareness regarding multiplex biomarker imaging and cloud-enabled technologies, especially in developing countries, is restraining the growth of the market. Also, the high cost of multiplex biomarker imaging devices is prohibiting the adoption of these devices in research laboratories dealing with cancer research.
The coronavirus continues its march around the globe, disrupting nearly every business around the world. The market observed a huge slowdown in its growth due to the spread of the Covid-19 pandemic worldwide.
As a result of pandemic-related lockdowns in different countries and disruptions in the supply chain of medical equipment, the multiplex biomarker imaging market witnessed a drop during the lockdown period.
Also, the manufacturers encountered several operational challenges that initially hampered their business activities during the lockdown. Ultimately, with the relaxation of the lockdown and the exceptional demand for diagnosis, the sales of multiple companies have grown positively. But, in the case of the multiplex biomarker imaging market, as these are playing a vital role in the development of therapies for chronic diseases, where pharmaceutical and government industries are expected to spend a lot, the market is expected to boost during the forecast period.
What Makes the USA a Large Market for Multiplex Biomarker Imaging?
The USA is estimated to account for around 91.3% of the North American multiplex biomarker imaging market in 2022.
The growing prevalence of chronic diseases, like cancer, rising demand for personalized and targeted medicine, favorable government initiatives, and growing aging population are the key factors contributing to the growth of the market in the USA The development can also be due to the availability of sophisticated diagnostics laboratories and great adoption rate of novel assay technologies. In addition, nearly every pharmaceutical manufacturer has been developing molecular biomarker products, either through different ventures or partnerships.
Germany is estimated to account for 20.2% of the Europe multiplex biomarker imaging market in Europe in 2022.
The growth of the market in Germany is because of the growing demand for automated equipment and the commercialization of multipurpose instruments with cloud-enabled technologies in many labs and research facilities. In addition, growing cancer research funding by biotech and pharmaceutical companies is leading to increased biomarker discovery which is contributing to market development. Also, the growing prevalence of cancer is resulting in greater adoption of these biomarkers for early diagnosis which is increasing the demand for the market in Germany.
The multiplex biomarker imaging market in Japan is estimated to be worth US$ 21.8 Million in 2022 in the global market.
The major factors responsible for the development of the market in Japan are the existence of a huge patient pool, rising focus on efficient and rapid diagnostics because of the rising incidence of chronic diseases, the presence of manufacturers in Japan, and increasing investment to improve robust healthcare facilities.
Moreover, rising awareness concerning the significance of biomarkers in clinical diagnostics, developments in drug discovery and manufacturing processes, and growing clinical studies to understand the role of biomarkers in the prognosis and diagnosis of complex diseases is expected to have a favorable effect on the growth of the market.
Demand for multiplex biomarker imaging in India is expected to rise at around 6.6% CAGR over the forecast period.
Increased focus on cancer research and increased demand for testing of non-small cell lung cancer are primary factors leading to the growth of the market in India. There is an increased focus on cancer research in India. Also, there is increased awareness for better diagnosis and focus on the establishment of better research facilities in the country. Thus, increased access to better healthcare and diagnostic infrastructure and the establishment of translational laboratories are factors fueling the demand for better imaging systems.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
By component type, the instruments segment is anticipated to hold the maximum share of 73.9% in 2022, expanding at a rate of nearly 11.8% during the forecast period.
The advantages offered by instruments like reliability, high image quality, and speed for entire slide imaging are encouraging the companies towards this instrument. Moreover, assessable pathology imaging systems, even though in their nascent stage, are adding to the potential sales forecasts for market players. Growing funding to develop advanced clinical and research laboratories has led to an increase in the purchase of these instruments, which is anticipated to contribute to the development of the segment.
By imaging technique, Immunohistochemistry (IHC) Assay will lead the market and is projected to account for 66.5% of the total market revenue share in 2022.
IHC is a histological method for identifying and localizing proteins in tissue specimens. This assay identifies some biomarkers such as oxidative stress, inflammation, tumors, and other diseases which assist in the diagnosis of complex diseases such as cancer using advanced methods. Thus, considering efficiency in regard to accuracy and processing time during the detection of target proteins in tissue specimens, immunohistochemistry (IHC) assays are expected to lead the market over the forecast period.
By application, research will be the most sought-after application and is projected to account for 86.5% of the total market revenue share in 2022.
Biomarkers are vital in medicine and play a significant role in research activities such as drug discovery and development. These can determine drug efficacy at a rapid pace in comparison to traditional clinical endpoints and are expected to fuel product development for serious disease indications. Thus, good success rates of biomarkers in drug discovery are increasing their application in research, which in turn is leading to segment growth.
By end user, the translational laboratories segment is anticipated to hold the maximum share of 47.8% in 2022, expanding at a rapid rate of 15.3% CAGR during the forecast period.
Multiplex Biomarker Imaging is utilized in translation laboratories as they offer a high-resolution methodology for creating immunohistochemistry images and precise scores of biomarkers. This method also aids to speed up the procedure by decreasing the number of slides needed per marker, which leads to time-saving while performing analysis.
Companies operating in the Multiplex Biomarker Imaging market are moderately competitive by nature, with a presence of few players. These players are involved in a number of strategic alliances. The product launch and acquisition accelerate the manufacturer’s strategy to capitalize on the market share and capture a significant share of the market. Some of the recent instances include:
Attribute | Details |
---|---|
Forecast Period | 2012 to 2021 |
Historical Data Available for | 2022 to 2029 |
Market Analysis | USD Million for Value and Units for Volume |
Key Countries Covered | The USA, Canada, Brazil, Mexico, Germany, Argentina, The UK, Germany, France, Italy, Spain, Nordic, Benelux, Russia, Poland, China, Japan, India, Thailand, Malaysia, Indonesia, Australia, New Zealand, GCC Countries, South Africa |
Key Segments Covered | Component Type, Imaging Technique, Application, End User, and Region |
Key Companies Profiled |
|
Report Coverage | Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
Customization & Pricing | Available upon Request |
By Component Type:
By Imaging Technique:
By Application:
By End User:
By Region:
The global multiplex biomarker imaging market is worth US$ 422.1 Million in 2021 and is set to expand 2.2X over the forecasted years owing to the rising cancer research and growing demand for personalized medicine.
The sales of Multiplex Biomarker Imaging in the market have grown at a CAGR of nearly 13.5% between 2012 and 2021. Increasing prevalence of chronic diseases and development in imaging assays is responsible for growth over the years.
The multiplex biomarker imaging market is expected to reach US$ 1,041.7 Million by the end of 2029 with sales revenue expected to register a CAGR of 11.9% over the forecast period.
North America currently holds the largest market share of around 57.0% in 2022 in the multiplex biomarker imaging market globally with the USA being the leading contributor with a market value of over US$ 247.3 Million in the North America market in 2022.
The demand for the multiplex biomarker imaging market is expected to register growth in Western Europe at a rate of 11.3% CAGR during the forecast period.
The Multiplex Biomarker Imaging in Japan is likely to observe growth with an impressive CAGR of 11.7% during the forecast period. The major factors responsible for the development of the market in Japan are the existence of a huge patient pool, rising focus on efficient and rapid diagnostics because of the rising incidence of chronic diseases, the presence of manufacturers in Japan, and increasing investment to improve robust healthcare facilities.
Growing adoption of IHC processes in immunofluorescence imaging and rising demand for large data set analysis are key trends driving sales of multiplex biomarker imaging market across the globe.
China’s Multiplex Biomarker Imaging market is offering lucrative growth opportunities and is expected to exhibit healthy growth of 12.0% CAGR during the forecast period. India's market is expected to exhibit healthy growth of 6.6% CAGR during the forecast period.
The USA, Germany, Canada, Japan, and the UK are the top 5 countries that are driving the demand for the multiplex biomarker imaging market.
Leading companies of multiplex biomarker imaging are PerkinElmer Inc., Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., Abcam plc., Merck KGaA, Illumina Inc., Leica Biosystems Nussloch GmbH (Danaher Corporation), Ventana Medical Systems, Inc. (A F. Hoffmann-La Roche AG Subsidiary), Aushon BioSystems Ltd., MicroConstants, Inc., and ToposNomos Ltd. (TNL)
1. Executive Summary | Multiplex Biomarker Imaging Market 1.1. Market Overview 1.2. Market Analysis 1.3. FMI Analysis and Recommendations 1.4. Wheel of Fortune 2. Market Introduction 2.1. Market Taxonomy 2.2. Market Definition 3. Market View Point 3.1. Macro-Economic Factors 3.2. Opportunity Analysis 3.3. Trends 3.4. Restraints 3.5. Pricing Analysis 2021 to 2029 4. North America Market Analysis 2012 to 2021 and Forecast 2022 to 2029 4.1. Introduction 4.2. Regional Market Dynamics 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Trends 4.3. Historical Market Size (US$ Million) Analysis By Country, 2012 to 2021 4.3.1. The USA 4.3.2. Canada 4.4. Market Size (US$ Million) Forecast By Country, 2022 to 2029 4.4.1. The USA 4.4.2. Canada 4.5. Historical Market Size (US$ Million) and Volume Analysis By Component Type, 2012 to 2021 4.5.1. Instruments 4.5.1.1. Quantitative Pathology Imaging System 4.5.1.2. Immunofluorescence Slide Scanner 4.5.1.3. Multispectral Imaging Systems 4.5.1.4. Toponome imaging System 4.5.2. Software 4.5.3. Services 4.5.3.1. Installation & Integration Services 4.5.3.2. Maintenance Service 4.6. Market Size (US$ Million) and Volume Forecast By Component Type, 2022 to 2029 4.6.1. Instruments 4.6.1.1. Quantitative Pathology Imaging System 4.6.1.2. Immunofluorescence Slide Scanner 4.6.1.3. Multispectral Imaging Systems 4.6.1.4. Toponome imaging System 4.6.2. Software 4.6.3. Services 4.6.3.1. Installation & Integration Services 4.6.3.2. Maintenance Service 4.7. Historical Market Size (US$ Million) Analysis by Imaging Technique, 2012 to 2021 4.7.1. Immunohistochemistry (IHC) Assay 4.7.2. Fluorescent In Situ Hybridization (FISH) Assay 4.7.3. Tissue Microarray (TMA) Assay 4.8. Market Size (US$ Million) Forecast, by Imaging Technique, 2022 to 2029 4.8.1. Immunohistochemistry (IHC) Assay 4.8.2. Fluorescent In Situ Hybridization (FISH) Assay 4.8.3. Tissue Microarray (TMA) Assay 4.9. Historical Market Size (US$ Million) Analysis by Application, 2012 to 2021 4.9.1. Research 4.9.2. Clinical Diagnostics 4.10. Market Size (US$ Million) Forecast, by Application, 2022 to 2029 4.10.1. Research 4.10.2. Clinical Diagnostics 4.11. Historical Market Size (US$ Million) Analysis by Application, 2012 to 2021 4.11.1. Translational Laboratories 4.11.2. Biopharmaceutical Companies 4.11.3. Academic Institutes 4.12. Market Size (US$ Million) Forecast, by Application, 2022 to 2029 4.12.1. Translational Laboratories 4.12.2. Biopharmaceutical Companies 4.12.3. Academic Institutes 4.13. Drivers and Restraints: Impact Analysis 4.14. Market Attractiveness Analysis 4.14.1. By Country 4.14.2. By Component Type 4.14.3. By Imaging Technique 4.14.4. Application 4.14.5. End User 4.15. Key Representative Market Presence (Intensity Map) 5. Latin America Market Analysis 2012 to 2021 and Forecast 2022 to 2029 5.1. Introduction 5.2. Regional Market Dynamics 5.2.1. Drivers 5.2.2. Restraints 5.2.3. Trends 5.3. Historical Market Size (US$ Million) Analysis By Country, 2012 to 2021 5.3.1. Brazil 5.3.2. Mexico 5.3.3. Argentina 5.3.4. Rest of Latin America 5.4. Market Size (US$ Million) Forecast By Country, 2022 to 2029 5.4.1. Brazil 5.4.2. Mexico 5.4.3. Argentina 5.4.4. Rest of Latin America 5.5. Historical Market Size (US$ Million) and Volume Analysis By Component Type, 2012 to 2021 5.5.1. Instruments 5.5.1.1. Quantitative Pathology Imaging System 5.5.1.2. Immunofluorescence Slide Scanner 5.5.1.3. Multispectral Imaging Systems 5.5.1.4. Toponome imaging System 5.5.2. Software 5.5.3. Services 5.5.3.1. Installation & Integration Services 5.5.3.2. Maintenance Service 5.6. Market Size (US$ Million) and Volume Forecast By Component Type, 2022 to 2029 5.6.1. Instruments 5.6.1.1. Quantitative Pathology Imaging System 5.6.1.2. Immunofluorescence Slide Scanner 5.6.1.3. Multispectral Imaging Systems 5.6.1.4. Toponome imaging System 5.6.2. Software 5.6.3. Services 5.6.3.1. Installation & Integration Services 5.6.3.2. Maintenance Service 5.7. Historical Market Size (US$ Million) Analysis by Imaging Technique, 2012 to 2021 5.7.1. Immunohistochemistry (IHC) Assay 5.7.2. Fluorescent In Situ Hybridization (FISH) Assay 5.7.3. Tissue Microarray (TMA) Assay 5.8. Market Size (US$ Million) Forecast, by Imaging Technique, 2022 to 2029 5.8.1. Immunohistochemistry (IHC) Assay 5.8.2. Fluorescent In Situ Hybridization (FISH) Assay 5.8.3. Tissue Microarray (TMA) Assay 5.9. Historical Market Size (US$ Million) Analysis by Application, 2012 to 2021 5.9.1. Research 5.9.2. Clinical Diagnostics 5.10. Market Size (US$ Million) Forecast, by Application, 2022 to 2029 5.10.1. Research 5.10.2. Clinical Diagnostics 5.11. Historical Market Size (US$ Million) Analysis by Application, 2012 to 2021 5.11.1. Translational Laboratories 5.11.2. Biopharmaceutical Companies 5.11.3. Academic Institutes 5.12. Market Size (US$ Million) Forecast, by Application, 2022 to 2029 5.12.1. Translational Laboratories 5.12.2. Biopharmaceutical Companies 5.12.3. Academic Institutes 5.13. Drivers and Restraints: Impact Analysis 5.14. Market Attractiveness Analysis 5.14.1. By Country 5.14.2. By Component Type 5.14.3. By Imaging Technique 5.14.4. Application 5.14.5. End User 5.15. Key Representative Market Presence (Intensity Map) 6. Western Europe Market Analysis 2012 to 2021 and Forecast 2022 to 2029 6.1. Introduction 6.2. Regional Market Dynamics 6.2.1. Drivers 6.2.2. Restraints 6.2.3. Trends 6.3. Historical Market Size (US$ Million) Analysis By Country, 2012 to 2021 6.3.1. The UK 6.3.2. Germany 6.3.3. France 6.3.4. Italy 6.3.5. Spain 6.3.6. Nordics 6.3.7. BENELUX 6.3.8. Rest of Western Europe 6.4. Market Size (US$ Million) Forecast By Country, 2022 to 2029 6.4.1. The UK 6.4.2. Germany 6.4.3. France 6.4.4. Italy 6.4.5. Spain 6.4.6. Nordics 6.4.7. BENELUX 6.4.8. Rest of Western Europe 6.5. Historical Market Size (US$ Million) and Volume Analysis By Component Type, 2012 to 2021 6.5.1. Instruments 6.5.1.1. Quantitative Pathology Imaging System 6.5.1.2. Immunofluorescence Slide Scanner 6.5.1.3. Multispectral Imaging Systems 6.5.1.4. Toponome imaging System 6.5.2. Software 6.5.3. Services 6.5.3.1. Installation & Integration Services 6.5.3.2. Maintenance Service 6.6. Market Size (US$ Million) and Volume Forecast By Component Type, 2022 to 2029 6.6.1. Instruments 6.6.1.1. Quantitative Pathology Imaging System 6.6.1.2. Immunofluorescence Slide Scanner 6.6.1.3. Multispectral Imaging Systems 6.6.1.4. Toponome imaging System 6.6.2. Software 6.6.3. Services 6.6.3.1. Installation & Integration Services 6.6.3.2. Maintenance Service 6.7. Historical Market Size (US$ Million) Analysis by Imaging Technique, 2012 to 2021 6.7.1. Immunohistochemistry (IHC) Assay 6.7.2. Fluorescent In Situ Hybridization (FISH) Assay 6.7.3. Tissue Microarray (TMA) Assay 6.8. Market Size (US$ Million) Forecast, by Imaging Technique, 2022 to 2029 6.8.1. Immunohistochemistry (IHC) Assay 6.8.2. Fluorescent In Situ Hybridization (FISH) Assay 6.8.3. Tissue Microarray (TMA) Assay 6.9. Historical Market Size (US$ Million) Analysis by Application, 2012 to 2021 6.9.1. Research 6.9.2. Clinical Diagnostics 6.10. Market Size (US$ Million) Forecast, by Application, 2022 to 2029 6.10.1. Research 6.10.2. Clinical Diagnostics 6.11. Historical Market Size (US$ Million) Analysis by Application, 2012 to 2021 6.11.1. Translational Laboratories 6.11.2. Biopharmaceutical Companies 6.11.3. Academic Institutes 6.12. Market Size (US$ Million) Forecast, by Application, 2022 to 2029 6.12.1. Translational Laboratories 6.12.2. Biopharmaceutical Companies 6.12.3. Academic Institutes 6.13. Drivers and Restraints: Impact Analysis 6.14. Market Attractiveness Analysis 6.14.1. By Country 6.14.2. By Component Type 6.14.3. By Imaging Technique 6.14.4. Application 6.14.5. End User 6.15. Key Representative Market Presence (Intensity Map) 7. Eastern Europe Market Analysis 2012 to 2021 and Forecast 2022 to 2029 7.1. Introduction 7.2. Historical Market Size (US$ Million) Analysis By Country, 2012 to 2021 7.2.1. Russia 7.2.2. Poland 7.2.3. Rest of Eastern Europe 7.3. Market Size (US$ Million) Forecast By Country,2022 to 2029 7.3.1. Russia 7.3.2. Poland 7.3.3. Rest of Eastern Europe 7.4. Historical Market Size (US$ Million) and Volume Analysis By Component Type, 2012 to 2021 7.4.1. Instruments 7.4.1.1. Quantitative Pathology Imaging System 7.4.1.2. Immunofluorescence Slide Scanner 7.4.1.3. Multispectral Imaging Systems 7.4.1.4. Toponome imaging System 7.4.2. Software 7.4.3. Services 7.4.3.1. Installation & Integration Services 7.4.3.2. Maintenance Service 7.5. Market Size (US$ Million) and Volume Forecast By Component Type, 2022 to 2029 7.5.1. Instruments 7.5.1.1. Quantitative Pathology Imaging System 7.5.1.2. Immunofluorescence Slide Scanner 7.5.1.3. Multispectral Imaging Systems 7.5.1.4. Toponome imaging System 7.5.2. Software 7.5.3. Services 7.5.3.1. Installation & Integration Services 7.5.3.2. Maintenance Service 7.6. Historical Market Size (US$ Million) Analysis by Imaging Technique, 2012 to 2021 7.6.1. Immunohistochemistry (IHC) Assay 7.6.2. Fluorescent In Situ Hybridization (FISH) Assay 7.6.3. Tissue Microarray (TMA) Assay 7.7. Market Size (US$ Million) Forecast, by Imaging Technique, 2022 to 2029 7.7.1. Immunohistochemistry (IHC) Assay 7.7.2. Fluorescent In Situ Hybridization (FISH) Assay 7.7.3. Tissue Microarray (TMA) Assay 7.8. Historical Market Size (US$ Million) Analysis by Application, 2012 to 2021 7.8.1. Research 7.8.2. Clinical Diagnostics 7.9. Market Size (US$ Million) Forecast, by Application, 2022 to 2029 7.9.1. Research 7.9.2. Clinical Diagnostics 7.10. Historical Market Size (US$ Million) Analysis by Application, 2012 to 2021 7.10.1. Translational Laboratories 7.10.2. Biopharmaceutical Companies 7.10.3. Academic Institutes 7.11. Market Size (US$ Million) Forecast, by Application, 2022 to 2029 7.11.1. Translational Laboratories 7.11.2. Biopharmaceutical Companies 7.11.3. Academic Institutes 7.12. Market Attractiveness Analysis 7.12.1. By Country 7.12.2. By Component Type 7.12.3. By Imaging Technique 7.12.4. Application 7.12.5. End User 7.13. Key Representative Market Presence (Intensity Map) 8. Asia-Pacific Excluding Japan (APEJ) Market Analysis 2012 to 2021 and Forecast 2022 to 2029 8.1. Introduction 8.2. Regional Market Dynamics 8.2.1. Drivers 8.2.2. Restraints 8.2.3. Trends 8.3. Historical Market Size (US$ Million) Analysis By Country, 2012 to 2021 8.3.1. China 8.3.2. India 8.3.3. Australia and New Zealand 8.3.4. ASEAN 8.3.5. Rest of APEJ 8.4. Market Size (US$ Million) Forecast By Country, 2022 to 2029 8.4.1. China 8.4.2. India 8.4.3. Australia and New Zealand 8.4.4. ASEAN 8.4.5. Rest of APEJ 8.5. Historical Market Size (US$ Million) and Volume Analysis By Component Type, 2012 to 2021 8.5.1. Instruments 8.5.1.1. Quantitative Pathology Imaging System 8.5.1.2. Immunofluorescence Slide Scanner 8.5.1.3. Multispectral Imaging Systems 8.5.1.4. Toponome imaging System 8.5.2. Software 8.5.3. Services 8.5.3.1. Installation & Integration Services 8.5.3.2. Maintenance Service 8.6. Market Size (US$ Million) and Volume Forecast By Component Type, 2022 to 2029 8.6.1. Instruments 8.6.1.1. Quantitative Pathology Imaging System 8.6.1.2. Immunofluorescence Slide Scanner 8.6.1.3. Multispectral Imaging Systems 8.6.1.4. Toponome imaging System 8.6.2. Software 8.6.3. Services 8.6.3.1. Installation & Integration Services 8.6.3.2. Maintenance Service 8.7. Historical Market Size (US$ Million) Analysis by Imaging Technique, 2012 to 2021 8.7.1. Immunohistochemistry (IHC) Assay 8.7.2. Fluorescent In Situ Hybridization (FISH) Assay 8.7.3. Tissue Microarray (TMA) Assay 8.8. Market Size (US$ Million) Forecast, by Imaging Technique, 2022 to 2029 8.8.1. Immunohistochemistry (IHC) Assay 8.8.2. Fluorescent In Situ Hybridization (FISH) Assay 8.8.3. Tissue Microarray (TMA) Assay 8.9. Historical Market Size (US$ Million) Analysis by Application, 2012 to 2021 8.9.1. Research 8.9.2. Clinical Diagnostics 8.10. Market Size (US$ Million) Forecast, by Application, 2022 to 2029 8.10.1. Research 8.10.2. Clinical Diagnostics 8.11. Historical Market Size (US$ Million) Analysis by Application, 2012 to 2021 8.11.1. Translational Laboratories 8.11.2. Biopharmaceutical Companies 8.11.3. Academic Institutes 8.12. Market Size (US$ Million) Forecast, by Application, 2022 to 2029 8.12.1. Translational Laboratories 8.12.2. Biopharmaceutical Companies 8.12.3. Academic Institutes 8.13. Drivers and Restraints: Impact Analysis 8.14. Market Attractiveness Analysis 8.14.1. By Country 8.14.2. By Component Type 8.14.3. By Imaging Technique 8.14.4. Application 8.14.5. End User 8.15. Key Representative Market Presence (Intensity Map) 9. Japan Market Analysis 2012 to 2021 and Forecast 2022 to 2029 9.1. Introduction 9.2. Historical Market Size (US$ Million) and Volume Analysis By Component Type, 2012 to 2021 9.2.1. Instruments 9.2.1.1. Quantitative Pathology Imaging System 9.2.1.2. Immunofluorescence Slide Scanner 9.2.1.3. Multispectral Imaging Systems 9.2.1.4. Toponome imaging System 9.2.2. Software 9.2.3. Services 9.2.3.1. Installation & Integration Services 9.2.3.2. Maintenance Service 9.3. Market Size (US$ Million) and Volume Forecast By Component Type, 2022 to 2029 9.3.1. Instruments 9.3.1.1. Quantitative Pathology Imaging System 9.3.1.2. Immunofluorescence Slide Scanner 9.3.1.3. Multispectral Imaging Systems 9.3.1.4. Toponome imaging System 9.3.2. Software 9.3.3. Services 9.3.3.1. Installation & Integration Services 9.3.3.2. Maintenance Service 9.4. Historical Market Size (US$ Million) Analysis by Imaging Technique, 2012 to 2021 9.4.1. Immunohistochemistry (IHC) Assay 9.4.2. Fluorescent In Situ Hybridization (FISH) Assay 9.4.3. Tissue Microarray (TMA) Assay 9.5. Market Size (US$ Million) Forecast, by Imaging Technique, 2022 to 2029 9.5.1. Immunohistochemistry (IHC) Assay 9.5.2. Fluorescent In Situ Hybridization (FISH) Assay 9.5.3. Tissue Microarray (TMA) Assay 9.6. Historical Market Size (US$ Million) Analysis by Application, 2012 to 2021 9.6.1. Research 9.6.2. Clinical Diagnostics 9.7. Market Size (US$ Million) Forecast, by Application, 2022 to 2029 9.7.1. Research 9.7.2. Clinical Diagnostics 9.8. Historical Market Size (US$ Million) Analysis by Application, 2012 to 2021 9.8.1. Translational Laboratories 9.8.2. Biopharmaceutical Companies 9.8.3. Academic Institutes 9.9. Market Size (US$ Million) Forecast, by Application, 2022 to 2029 9.9.1. Translational Laboratories 9.9.2. Biopharmaceutical Companies 9.9.3. Academic Institutes 9.10. Market Attractiveness Analysis 9.10.1. By Component Type 9.10.2. By Imaging Technique 9.10.3. Application 9.10.4. End User 9.11. Key Representative Market Presence (Intensity Map) 10. Middle East and Africa Market Analysis 2012 to 2021 and Forecast 2022 to 2029 10.1. Introduction 10.2. Regional Market Dynamics 10.2.1. Drivers 10.2.2. Restraints 10.2.3. Trends 10.3. Historical Market Size (US$ Million) Analysis By Country, 2012 to 2021 10.3.1. GCC Countries 10.3.2. South Africa 10.3.3. Rest of MEA 10.4. Market Size (US$ Million) Forecast By Country, 2022-2029 10.4.1. GCC Countries 10.4.2. South Africa 10.4.3. Rest of MEA 10.5. Historical Market Size (US$ Million) and Volume Analysis By Component Type, 2012 to 2021 10.5.1. Instruments 10.5.1.1. Quantitative Pathology Imaging System 10.5.1.2. Immunofluorescence Slide Scanner 10.5.1.3. Multispectral Imaging Systems 10.5.1.4. Toponome imaging System 10.5.2. Software 10.5.3. Services 10.5.3.1. Installation & Integration Services 10.5.3.2. Maintenance Service 10.6. Market Size (US$ Million) and Volume Forecast By Component Type, 2022 to 2029 10.6.1. Instruments 10.6.1.1. Quantitative Pathology Imaging System 10.6.1.2. Immunofluorescence Slide Scanner 10.6.1.3. Multispectral Imaging Systems 10.6.1.4. Toponome imaging System 10.6.2. Software 10.6.3. Services 10.6.3.1. Installation & Integration Services 10.6.3.2. Maintenance Service 10.7. Historical Market Size (US$ Million) Analysis by Imaging Technique, 2012 to 2021 10.7.1. Immunohistochemistry (IHC) Assay 10.7.2. Fluorescent In Situ Hybridization (FISH) Assay 10.7.3. Tissue Microarray (TMA) Assay 10.8. Market Size (US$ Million) Forecast, by Imaging Technique, 2022 to 2029 10.8.1. Immunohistochemistry (IHC) Assay 10.8.2. Fluorescent In Situ Hybridization (FISH) Assay 10.8.3. Tissue Microarray (TMA) Assay 10.9. Historical Market Size (US$ Million) Analysis by Application, 2012 to 2021 10.9.1. Research 10.9.2. Clinical Diagnostics 10.10. Market Size (US$ Million) Forecast, by Application, 2022 to 2029 10.10.1. Research 10.10.2. Clinical Diagnostics 10.11. Historical Market Size (US$ Million) Analysis by Application, 2012 to 2021 10.11.1. Translational Laboratories 10.11.2. Biopharmaceutical Companies 10.11.3. Academic Institutes 10.12. Market Size (US$ Million) Forecast, by Application, 2022 to 2029 10.12.1. Translational Laboratories 10.12.2. Biopharmaceutical Companies 10.12.3. Academic Institutes 10.13. Drivers and Restraints: Impact Analysis 10.14. Market Attractiveness Analysis 10.14.1. By Country 10.14.2. By Component Type 10.14.3. By Imaging Technique 10.14.4. Application 10.14.5. End User 10.15. Key Representative Market Presence (Intensity Map) 11. Forecast Factors: Relevance and Impact 12. Forecast Assumptions 13. Competition Landscape 13.1. Competition Dashboard 13.2. Company Share Analysis 13.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments, and SWOT Analysis) 13.3.1. Perkin Elmer, Inc. 13.3.2. Bio-Rad Laboratories Inc. 13.3.3. Thermo Fisher Scientific, Inc. 13.3.4. Abcam plc. 13.3.5. Merck KGaA 13.3.6. Illumina Inc. 13.3.7. Leica Biosystems Nussloch GmbH 13.3.8. Ventana Medical Systems, Inc. 13.3.9. Aushon BioSystems Ltd. 13.3.10. MicroConstants, Inc. 13.3.11. ToposNomos Ltd. 14. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2029, By Region 14.1. Introduction / Key Findings 14.2. Historical Market Size (US$ Million) Analysis By Region, 2012 to 2021 14.2.1. North America 14.2.2. Latin America 14.2.3. Western Europe 14.2.4. Eastern Europe 14.2.5. Asia Pacific Excluding Japan 14.2.6. Japan 14.2.7. Middle East & Africa (MEA) 14.3. Market Size (US$ Million) Forecast By Region, 2022 to 2029 14.3.1. North America 14.3.2. Latin America 14.3.3. Western Europe 14.3.4. Eastern Europe 14.3.5. Asia Pacific Excluding Japan 14.3.6. Japan 14.3.7. Middle East and Africa 14.4. Market Attractiveness Analysis By Region 15. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2029, By Component Type 15.1. Introduction 15.2. Historical Market Size (US$ Million) and Volume Analysis By Component Type, 2012 to 2021 15.2.1. Instruments 15.2.1.1. Quantitative Pathology Imaging System 15.2.1.2. Immunofluorescence Slide Scanner 15.2.1.3. Multispectral Imaging Systems 15.2.1.4. Toponome imaging System 15.2.2. Software 15.2.3. Services 15.2.3.1. Installation & Integration Services 15.2.4. Maintenance Service 15.3. Market Size (US$ Million) and Volume Forecast By Component Type,2022 to 2029 15.3.1. Instruments 15.3.1.1. Quantitative Pathology Imaging System 15.3.1.2. Immunofluorescence Slide Scanner 15.3.1.3. Multispectral Imaging Systems 15.3.1.4. Toponome imaging System 15.3.2. Software 15.3.3. Services 15.3.3.1. Installation & Integration Services 15.3.4. Maintenance Service 15.4. Market Attractiveness Analysis by Component Type 16. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2029, By Imaging Technique 16.1. Introduction 16.2. Historical Market Size (US$ Million) Analysis, by Imaging Technique, 2012 to 2021 16.2.1. Immunohistochemistry (IHC) Assay 16.2.2. Fluorescent In Situ Hybridization (FISH) Assay 16.2.3. Tissue Microarray (TMA) Assay 16.3. Market Size (US$ Million) Forecast, by Imaging Technique, 2022 to 2029 16.3.1. Immunohistochemistry (IHC) Assay 16.3.2. Fluorescent In Situ Hybridization (FISH) Assay 16.3.3. Tissue Microarray (TMA) Assay 16.4. Market Attractiveness Analysis by Imaging Technique 17. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2029, By Application 17.1. Introduction 17.2. Historical Market Size (US$ Million) Analysis, by Application, 2012 to 2021 17.2.1. Research 17.2.2. Clinical Diagnostics 17.3. Market Size (US$ Million) Forecast, by Application, 2022 to 2029 17.3.1. Research 17.3.2. Clinical Diagnostics 17.4. Market Attractiveness Analysis by Application 18. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2029, By End User 18.1. Introduction 18.2. Historical Market Size (US$ Million) Analysis, by End User, 2012 to 2021 18.2.1. Translational Laboratories 18.2.2. Biopharmaceutical Companies 18.2.3. Academic Institutes 18.3. Market Size (US$ Million) Forecast, by End User, 2022 to 2029 18.3.1. Translational Laboratories 18.3.2. Biopharmaceutical Companies 18.3.3. Academic Institutes 18.4. Market Attractiveness Analysis by End User 19. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2029 19.1. Market Size and Y-o-Y Growth 19.2. Absolute $ Opportunity 20. Assumptions and Acronyms Used 21. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Table 01: CPT Codes for Digital Pathology Table 02: DPA Regulatory FDA 510(k) List Table 03: DPA Regulatory FDA 510(k) List Table 04: North America Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2029, By Component Type Table 05: North America Market Volume Analysis 2012 to 2021 and Forecast 2022 to 2029, By Component Type Table 06: North America Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2029, By Imaging Technique Table 07: North America Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2029, By Application Table 08: North America Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2029, By End User Table 09: North America Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2029, By Country Table 10: North America Participants Presence (Intensity Mapping) Table 11: Latin America Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2029, By Component Type Table 12: Latin America Market Volume Analysis 2012 to 2021 and Forecast 2022 to 2029, By Component Type Table 13: Latin America Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2029, By Imaging Technique Table 14: Latin America Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2029, By Application Table 15: Latin America Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2029, By End User Table 16: Latin America Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2029, By Country Table 17: Latin America Participants Presence (Intensity Mapping) Table 18: Western Europe Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2029, By Component Type Table 19: Western Europe Market Volume Analysis-2012 to 2021 and Forecast 2022 to 2029, By Component Type Table 20: Western Europe Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2029, By Imaging Technique Table 21: Western Europe Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2029, By Application Table 22: Western Europe Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2029, By End User Table 23: Western Europe Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2029, By Country Table 24: Western Europe Participants Presence (Intensity Mapping) Table 25: Eastern Europe Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2029, By Component Type Table 26: Eastern Europe Market Volume Analysis 2012 to 2021 and Forecast 2022 to 2029, By Component Type Table 27: Eastern Europe Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2029, By Imaging Technique Table 28: Eastern Europe Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2029, By Application Table 29: Eastern Europe Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2029, By End User Table 30: Eastern Europe Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2029, By Country Table 31: Eastern Europe Participants Presence (Intensity Mapping) Table 32: APEJ Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2029, By Component Type Table 33: APEJ Market Volume Analysis-2012 to 2021 and Forecast 2022 to 2029, By Component Type Table 34: APEJ Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2029, By Imaging Technique Table 35: APEJ Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2029, By Application Table 36: APEJ Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2029, By End User Table 37: APEJ Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2029, By Country Table 38: APEJ Participants Presence (Intensity Mapping) Table 39: Japan Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2029, By Component Type Table 40: Japan Market Volume Analysis 2012 to 2021 and Forecast 2022 to 2029, By Component Type Table 41: Japan Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2029, By Imaging Technique Table 42: Japan Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2029, By Application Table 43: Japan Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2029, By End User Table 44: Japan Participants Presence (Intensity Mapping) Table 45: MEA Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2029, By Component Type Table 46: MEA Market Volume Analysis-2012 to 2021 and Forecast 2022 to 2029, By Component Type Table 47: MEA Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2029, By Imaging Technique Table 48: MEA Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2029, By Application Table 49: MEA Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2029, By End User Table 50: MEA Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2029, By Country Table 51: MEA Participants Presence (Intensity Mapping) Table 52: Global Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2029, By Region Table 53: Global Market Value (US$ Million) Analysis-2012 to 2021 and Forecast 2022 to 2029, By Component Type Table 54: Global Market Volume Analysis 2012 to 2021 and Forecast 2022 to 2029, By Component Type Table 55: Global Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2029, By Imaging Technique Table 56: Global Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2029, By Application Table 57: Global Market Value (US$ Million) Analysis 2012 to 2021 and Forecast 2022 to 2029, By End User
Figure 01: The USA FDA Regulatory Approval for Medical Devices Figure 02: Europe Regulatory Approval for Medical Devices Figure 03: Japan Regulatory Approval for Medical Devices Figure 04: North America Market Value Share by Component Type (2022) Figure 06: North America Market Value Share by Application (2022) Figure 05: North America Market Value Share by Imaging Technique (2022) Figure 07: North America Market Value Share by End User (2022) Figure 08: North America Market Value Share by Country (2022) Figure 09: North America Historical Market Analysis 2012 to 2021 Figure 10: North America Market Forecast, 2022 to 2029 Figure 11: The USA Historical Market Analysis 2012 to 2021 Figure 12: The USA Market Forecast, 2022 to 2029 Figure 13: Canada Historical Market Analysis 2012 to 2021 Figure 14: Canada Market Forecast, 2022 to 2029 Figure 15: North America Market Attractive Analysis by Component Type, 2022 to 2029 Figure 16: North America Market Attractive Analysis by Imaging Technique, 2022 to 2029 Figure 17: North America Market Attractive Analysis by Application, 2022 to 2029 Figure 18: North America Market Attractive Analysis by End User, 2022 to 2029 Figure 19: North America Market Attractive Analysis by Country, 2022 to 2029 Figure 20: North America - Drivers & Restrains Impact Analysis Figure 21: Latin America Market Value Share by Component Type (2022) Figure 23: Latin America Market Value Share by Application (2022) Figure 22: Latin America Market Value Share by Imaging Technique (2022) Figure 24: Latin America Market Value Share by End User (2022) Figure 25: Latin America Market Value Share by Country (2022) Figure 26: Latin America Historical Market Analysis 2012 to 2021 Figure 27: Latin America Market Forecast, 2022 to 2029 Figure 28: Brazil Historical Market Analysis 2012 to 2021 Figure 29: Brazil Market Forecast, 2022 to 2029 Figure 30: Mexico Historical Market Analysis 2012 to 2021 Figure 31: Mexico Market Forecast, 2022 to 2029 Figure 32: Argentina Historical Market Analysis 2012 to 2021 Figure 33: Argentina Market Forecast, 2022 to 2029 Figure 34: Rest of Latin America Historical Market Analysis 2012 to 2021 Figure 35: Rest of Latin America Market Forecast, 2012 to 2021 Figure 36: Latin America Market Attractive Analysis by Component Type, 2022 to 2029 Figure 37: Latin America Market Attractive Analysis by Imaging Technique, 2022 to 2029 Figure 38: Latin America Market Attractive Analysis by Application, 2022 to 2029 Figure 39: Latin America Market Attractive Analysis by End User, 2022 to 2029 Figure 40: Latin America Market Attractive Analysis by Country, 2022 to 2029 Figure 41: Latin America - Drivers & Restraint Impact Analysis Figure 42: Western Europe Market Value Share by Component Type (2022) Figure 44: Western Europe Market Value Share by Application (2022) Figure 43: Western Europe Market Value Share by Imaging Technique (2022) Figure 45: Western Europe Market Value Share by End User (2022) Figure 46: Western Europe Market Value Share by Country (2022) Figure 47: Western Europe Historical Market Analysis 2012 to 2021 Figure 48: Western Europe Market Forecast, 2022 to 2029 Figure 49: The UK Historical Market Analysis 2012 to 2021 Figure 50: The UK Market Forecast, 2022 to 2029 Figure 51: Germany Historical Market Analysis 2012 to 2021 Figure 52: Germany Market Forecast, 2022 to 2029 Figure 53: France Historical Market Analysis 2012 to 2021 Figure 54: France Market Forecast, 2022 to 2029 Figure 55: Italy Historical Market Analysis 2012 to 2021 Figure 56: Italy Market Forecast, 2022 to 2029 Figure 57: Spain Historical Market Analysis 2012 to 2021 Figure 58: Spain Market Forecast, 2022 to 2029 Figure 59: Nordics Historical Market Analysis 2012 to 2021 Figure 60: Nordics Market Forecast, 2022 to 2029 Figure 61: Benelux Historical Market Analysis 2012 to 2021 Figure 62: Benelux Market Forecast, 2022 to 2029 Figure 63: Rest of Western Europe Historical Market Analysis 2012 to 2021 Figure 64: Rest of Western Europe Market Forecast, 2022 to 2029 Figure 65: Western Europe Market Attractive Analysis by Component Type, 2022 to 2029 Figure 66: Western Europe Market Attractive Analysis by Imaging Technique, 2022 to 2029 Figure 67: Western Europe Market Attractive Analysis by Application, 2022 to 2029 Figure 68: Western Europe Market Attractive Analysis by End User, 2022 to 2029 Figure 69: Western Europe Market Attractive Analysis by Component Type, 2022 to 2029 Figure 70: Europe - Drivers & Restraint Impact Analysis Figure 70: Eastern Europe Market Value Share by Component Type (2022) Figure 72: Eastern Europe Market Value Share by Application (2022) Figure 71: Eastern Europe Market Value Share by Imaging Technique (2022) Figure 73: Eastern Europe Market Value Share by End User (2022) Figure 74: Eastern Europe Market Value Share by Country (2022) Figure 75: Eastern Europe Historical Market Analysis 2012 to 2021 Figure 76: Eastern Europe Market Forecast, 2022 to 2029 Figure 77: Russia Historical Market Analysis 2012 to 2021 Figure 78: Russia Market Forecast, 2022 to 2029 Figure 79: Poland Historical Market Analysis 2012 to 2021 Figure 80: Poland Market Forecast, 2022 to 2029 Figure 81: Rest of Eastern Europe Historical Market Analysis 2012 to 2021 Figure 82: Rest of Eastern Europe Market Forecast, 2022 to 2029 Figure 83: Eastern Europe Market Attractive Analysis by Component Type, 2022 to 2029 Figure 84: Eastern Europe Market Attractive Analysis by Imaging Technique, 2022 to 2029 Figure 85: Eastern Europe Market Attractive Analysis by Application, 2022 to 2029 Figure 86: Eastern Europe Market Attractive Analysis by End User, 2022 to 2029 Figure 87: Eastern Europe Market Attractive Analysis by Component Type, 2022 to 2029 Figure 88: APEJ Market Value Share by Component Type (2022) Figure 90: APEJ Market Value Share by Application (2022) Figure 89: APEJ Market Value Share by Imaging Technique (2022) Figure 91: APEJ Market Value Share by End User (2022) Figure 92: APEJ Market Value Share by Country (2022) Figure 93: APEJ Historical Market Analysis 2012 to 2021 Figure 94: APEJ Market Forecast, 2022 to 2029 Figure 95: China Historical Market Analysis 2012 to 2021 Figure 96: China Market Forecast, 2022 to 2029 Figure 97: India Historical Market Analysis 2012 to 2021 Figure 98: India Market Forecast, 2022 to 2029 Figure 99: Australia and NZ Historical Market Analysis 2012 to 2021 Figure 100: Australia and NZ Market Forecast, 2022 to 2029 Figure 101: ASEAN Historical Market Analysis 2012 to 2021 Figure 102: ASEAN Market Forecast, 2022 to 2029 Figure 103: Rest of APEJ Historical Market Analysis 2012 to 2021 Figure 104: Rest of APEJ Market Forecast, 2022 to 2029 Figure 105: APEJ Market Attractive Analysis by Component Type, 2022 to 2029 Figure 106: APEJ Market Attractive Analysis by Imaging Technique, 2022 to 2029 Figure 107: APEJ Market Attractive Analysis by Application, 2022 to 2029 Figure 108: APEJ Market Attractive Analysis by End User, 2022 to 2029 Figure 109: APEJ Market Attractive Analysis by Component Type, 2022 to 2029 Figure 110: APAC Drivers & Restraint Impact Analysis Figure 111: Japan Market Value Share by Component Type (2022) Figure 113: Japan Market Value Share by Application (2022) Figure 112: Japan Market Value Share by Imaging Technique (2022) Figure 114: Japan Market Value Share by End User (2022) Figure 115: Japan Historical Market Analysis 2012 to 2021 Figure 116: Japan Market Forecast, 2022 to 2029 Figure 117: Japan Market Attractive Analysis by Component Type, 2022 to 2029 Figure 118: Japan Market Attractive Analysis by Imaging Technique, 2022 to 2029 Figure 119: Japan Market Attractive Analysis by Application, 2022 to 2029 Figure 120: Japan Market Attractive Analysis by End User, 2022 to 2029 Figure 121: MEA Market Value Share by Component Type (2022) Figure 123: MEA Market Value Share by Application (2022) Figure 122: MEA Market Value Share by Imaging Technique (2022) Figure 124: MEA Market Value Share by End User (2022) Figure 125: MEA Market Value Share by Country (2022) Figure 126: MEA Historical Market Analysis 2012 to 2021 Figure 127: MEA Market Forecast, 2022 to 2029 Figure 128: South Africa Historical Market Analysis 2012 to 2021 Figure 129: South Africa Market Forecast, 2022 to 2029 Figure 130: GCC Countries Historical Market Analysis 2012 to 2021 Figure 131: GCC Countries Market Forecast, 2022 to 2029 Figure 132: Rest of MEA Historical Market Analysis 2012 to 2021 Figure 133: Rest of MEA Market Forecast, 2022 to 2029 Figure 134: MEA Market Attractive Analysis by Component Type, 2022 to 2029 Figure 135: MEA Market Attractive Analysis by Imaging Technique, 2022 to 2029 Figure 136: MEA Market Attractive Analysis by Application, 2022 to 2029 Figure 137: MEA Market Attractive Analysis by End User, 2022 to 2029 Figure 138: MEA Market Attractive Analysis by Component Type, 2022 to 2029 Figure 139: MEA Drivers & Restraint Impact Analysis Figure 140: Global Market Share Analysis Figure 141: Global Market Attractive Analysis by Region, 2022 to 2029 Figure 142: Global Market Attractive Analysis by Component, 2022 to 2029 Figure 143: Global Market Attractive Analysis by Imaging Techniques, 2022 to 2029 Figure 144: Global Market Attractive Analysis by Application, 2022 to 2029 Figure 145: Global Market Attractive Analysis by End User, 2022 to 2029 Figure 146: Global Historical Market Analysis 2012 to 2021 Figure 147: Global Market Forecast, 2022 to 2029 Figure 148: Global Market Absolute $ Opportunity, 2012 to 2021 Figure 149: Global Market Absolute $ Opportunity, 2022 – 2029
Recommendations
Explore Healthcare Insights
View Reports